IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to TRYNGOLZA guidance. NEW YORK, Nov. 10, 2026 /PRNewswire/ -- A revenue beat did not stop the...
Covered in this story
Analyst targets on Ionis Pharmaceuticals
- Raymond James: at $39.4 · target $54 by Nov 2027 · Outperform via Investing.com
- BMO Capital Markets: at $44.3 · target $66 by Oct 2027 · Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $IONS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ionis Pharmaceuticals →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.